Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease

Authors

  • Andrea C. Paula-Lima,

    Corresponding author
    • Department of Basic Sciences, Faculty of Dentistry, University of Chile, Santiago, Chile
    Search for more papers by this author
  • Jordano Brito-Moreira,

    1. Institute of Medical Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
    Search for more papers by this author
  • Sergio T. Ferreira

    Corresponding author
    1. Institute of Medical Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
    • Department of Basic Sciences, Faculty of Dentistry, University of Chile, Santiago, Chile
    Search for more papers by this author

Address correspondence and reprint requests to Sergio T. Ferreira, Institute of Medical Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21944-590, Brazil. E-mail: ferreira@bioqmed.ufrj.br or Andrea C. Paula-Lima, Department of Basic Sciences, Faculty of Dentistry, University of Chile, Santiago, RM 8380-492, Chile. E-mail: apaula@med.uchile.cl

Abstract

Alzheimer′s disease (AD) is the most common form of dementia in the elderly. Memory loss in AD is increasingly attributed to soluble oligomers of the amyloid-β peptide (AβOs), toxins that accumulate in AD brains and target particular synapses. Glutamate receptors appear to be centrally involved in synaptic targeting by AβOs. Once bound to neurons, AβOs dysregulate the activity and reduce the surface expression of both N-methyl-d-aspartate (NMDA) and 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid (AMPA) types of glutamate receptors, impairing signaling pathways involved in synaptic plasticity. In the extracellular milieu, AβOs promote accumulation of the excitatory amino acids, glutamate and d-serine. This leads to overactivation of glutamate receptors, triggering abnormal calcium signals with noxious impacts on neurons. Here, we review key findings linking AβOs to deregulated glutamate neurotransmission and implicating this as a primary mechanism of synapse failure in AD. We also discuss strategies to counteract the impact of AβOs on excitatory neurotransmission. In particular, we review evidence showing that inducing neuronal hyperpolarization via activation of inhibitory GABAA receptors prevents AβO-induced excitotoxicity, suggesting that this could comprise a possible therapeutic approach in AD.

Ancillary